Shattuck Labs Boosts Board with Biotech Heavyweights
Company Announcements

Shattuck Labs Boosts Board with Biotech Heavyweights

Shattuck Labs (STTK) has provided an update.

Shattuck Labs, Inc. has announced the appointment of Dr. Kate Sasser and Dr. Clay Siegall to its Board of Directors, expanding the board’s expertise in the biotechnology and pharmaceutical sectors. Dr. Sasser brings a wealth of experience from her tenure at Tempus AI and Genmab A/S, alongside her scientific roles at Johnson and Johnson. Dr. Siegall, with a distinguished career including leadership at Immunome, Inc. and Seagen Inc., adds significant executive experience to the board. Their appointments are part of the company’s strategic positioning for future growth, reflecting a commitment to strong governance and innovative leadership in the healthcare technology arena.

Learn more about STTK stock on TipRanks’ Stock Analysis page.

Related Articles
Howard KimSTTK Upcoming Earnings Report: What to Expect?
TheFlyShattuck Labs downgraded to Hold from Buy at Needham
TheFlyShattuck Labs downgraded to Neutral from Buy at Citi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App